- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02610348
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
March 19, 2018 updated by: Sanofi Pasteur, a Sanofi Company
Persistence of Anti-Hep B Antibodies at 12 to 18 Months of Age in Children Having Received Hep B Vaccine at Birth and a DTaP-IPV-HB-Hib Hexavalent Vaccine (Hexaxim® or Infanrix Hexa®) Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Primary Objective:
To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6 months of age following Hep B vaccination at birth.
Study Overview
Status
Completed
Conditions
Detailed Description
Sera from subjects who have participated in study PNA19 trial (NCT00594347) and for whom parents or legal representatives had given authorization to use the sera taken from their child will be used for this study.
Study Type
Interventional
Enrollment (Actual)
122
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangkok, Thailand, 10700
-
Khon Kaen, Thailand, 40002
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects having received 4 Hep B doses in A3L12 (i.e. one dose at birth + three doses during study at 2, 4 & 6 months of age)
- Subjects having participated in PNA19
- Subject's parents having given authorization to use serum collected in PNA19 for future research
- The initials, birth date, and gender of the subject are consistent between A3L12 and PNA19 databases
- Subjects for whom retention sera are of enough volume to allow a valid determination of the HBsAg antibody level.
Exclusion Criteria:
- Not applicable.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A
Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
|
Original Vaccine in Study A3L12 (NCT00401531).
No vaccination will be administered as part of this study
|
EXPERIMENTAL: Group B
Toddlers vaccinated with Infanrix hexa® in study A3L12
|
Original Vaccine in Study A3L12 (NCT00401531).
No vaccination will be administered as part of this study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of anti-Hepatitis B antibody concentrations in subject that received Hexaxim® or Infanrix® hexa vaccine in a previous study
Time Frame: Day 0
|
Levels of anti-Hepatitis B antibody concentrations will be determined at ≥ 10 mIU/mL and ≥ 100 mIU/mL
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (ACTUAL)
December 1, 2015
Study Completion (ACTUAL)
March 1, 2016
Study Registration Dates
First Submitted
November 18, 2015
First Submitted That Met QC Criteria
November 19, 2015
First Posted (ESTIMATE)
November 20, 2015
Study Record Updates
Last Update Posted (ACTUAL)
March 20, 2018
Last Update Submitted That Met QC Criteria
March 19, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Hepatitis B
- Hepatitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- A3L47
- U1111-1161-2649 (OTHER: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Tongji HospitalGilead SciencesRecruiting
Clinical Trials on DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type bThailand
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Whooping Cough | Tetanus | Diphtheria | PoliomyelitisColombia, Costa Rica
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Diphtheria | PolioTurkey
-
Sanofi Pasteur, a Sanofi CompanyCompletedStudy of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsHepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type bPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Diphtheria | PolioTurkey
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Tetanus | Diphtheria | PoliomyelitisMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type bPeru, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type bArgentina
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Tetanus | Diphtheria | InfluenzaPhilippines
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type bSouth Africa